# Study of Troxatyl™ Administered by Continuous Infusion to Subjects With Solid Tumors

> **NCT00104286** · PHASE1,PHASE2 · TERMINATED · sponsor: **SGX Pharmaceuticals, Inc.** · enrollment: 50 (—)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** Troxatyl™ (Cytotoxic Chemotherapeutic)

## Key facts

- **NCT ID:** NCT00104286
- **Lead sponsor:** SGX Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-01
- **Primary completion:** —
- **Final completion:** 2005-11
- **Target enrollment:** 50 (—)
- **Last updated:** 2006-11-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00104286

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00104286, "Study of Troxatyl™ Administered by Continuous Infusion to Subjects With Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00104286. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*